ReviewCureus2025
Cell Salvage in the Management of Postpartum Hemorrhage: A Comprehensive Review of the Current Literature.
Review in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Postpartum hemorrhage (PPH) remains a leading contributor in maternal illness and death worldwide, and its incidence continues to rise. This has led to an increased reliance on allogeneic blood transfusions (ABT), which are limited in supply and carry significant health risks. Cell salvage (CS), which collects and transfuses a patient's own blood, has been proposed as a useful adjunct or alternative. This narrative review aims to evaluate and summarize the current literature on obstetric CS (OCS) in the management of PPH, with a focus on efficacy, safety, cost-effectiveness, and future research considerations. A literature search was performed using PubMed and Google Scholar, leading to the selection and review of 32 original articles published from 2015 onward. Single case reports, meta-analyses, and other review articles were excluded to minimize amplification bias and ensure an authentic analysis of primary research data. OCS has been shown to reduce the need for donor blood, especially during high-risk cesarean sections, including those with placenta previa and placenta accreta spectrum. Reported benefits include improved maternal hemoglobin, reduced transfusion-related complications, and shorter hospital stay. However, not all the results were statistically significant for reductions in allogeneic transfusion rates. Safety concerns associated with the use of OCS, including amniotic fluid embolism, sepsis, hemolysis, coagulopathy, and Rh alloimmunization, have been substantially addressed through advancements in technology, the implementation of leukocyte depletion filters, and the routine administration of anti-D prophylaxis. Evidence for its use in vaginal deliveries remains sparse, though early studies suggest technical feasibility. Cost-effectiveness is debated and appears dependent on institutional protocols, case volume, and technique optimization. OCS represents a safe and valuable blood-conservation strategy in obstetric practice, particularly for high-risk cesarean section. Wider adoption requires standardized protocols, staff training, and further multicenter research to clarify its role, especially in vaginal deliveries.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.